$ANAB
ANAPTYSBIO, INC Stock $anab

$anab Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000137005324000011 Filed on March 11, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$7.179M	$9.005M	$17.16M
YoY Change	422.49%	32.27%	66.78%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.34M	$10.28M	$41.95M
YoY Change	14.05%	9.24%	14.47%
% of Gross Profit
Research & Development	$37.04M	$40.86M	$132.3M
YoY Change	5.96%	74.83%	48.97%
% of Gross Profit
Depreciation & Amortization	$163.0K	$165.0K	$652.0K
YoY Change	-1.81%	-10.33%	-3.41%
% of Gross Profit
Operating Expenses	$49.38M	$51.14M	$181.6M
YoY Change	7.88%	56.01%	44.74%
Operating Profit	-$42.20M		-$164.4M
YoY Change	-4.95%		42.77%
Interest Expense	$4.584M	$4.880M	$18.87M
YoY Change	2.18%	27.12%	149.97%
% of Operating Profit
Other Income/Expense, Net	-$1.735M	-$4.960M	$788.0K
YoY Change	-1288.36%	16.57%	-105.82%
Pretax Income	-$43.94M	-$42.22M	-$163.6M
YoY Change	-0.72%	59.97%	27.14%
Income Tax		-$4.000K	-$4.000K
% Of Pretax Income
Net Earnings	-$43.94M	-$42.21M	-$163.6M
YoY Change	-0.72%	59.81%	27.11%
Net Earnings / Revenue	-612.01%	-468.75%	-953.66%
Basic Earnings Per Share	-$1.64		-$6.08
Diluted Earnings Per Share	-$1.64	-$1.59	-$6.08
COMMON SHARES
Basic Shares Outstanding	26.76M shares	26.58M shares	26.92M shares
Diluted Shares Outstanding	26.80M shares		26.92M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$354.7M	$390.9M	$390.9M
YoY Change	-17.74%	-11.41%	-11.41%
Cash & Equivalents	$53.70M	$35.97M	$35.97M
Short-Term Investments	$301.0M	$354.9M	$354.9M
Other Short-Term Assets	$10.67M	$9.080M	$9.080M
YoY Change	138.08%	99.78%	99.78%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$372.4M	$406.8M	$406.8M
YoY Change	-14.81%	-9.03%	-9.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.954M	$2.098M	$18.27M
YoY Change	-1.41%	0.43%	-8.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$15.47M	$27.03M	$27.03M
YoY Change	-83.7%	-81.09%	-81.09%
Other Assets	$256.0K	$256.0K	$256.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$33.42M	$45.55M	$45.55M
YoY Change	-70.85%	-72.08%	-72.08%
TOTAL ASSETS
Total Short-Term Assets	$372.4M	$406.8M	$406.8M
Total Long-Term Assets	$33.42M	$45.55M	$45.55M
Total Assets	$405.8M	$452.4M	$452.4M
YoY Change	-26.45%	-25.88%	-25.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.582M	$4.698M	$4.698M
YoY Change	44.63%	68.75%	68.75%
Accrued Expenses	$25.90M	$30.97M	$32.74M
YoY Change	-16.32%	43.15%	40.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$32.30M	$37.44M	$37.44M
YoY Change	-9.77%	43.71%	43.71%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$325.8M	$326.8M	$326.8M
YoY Change	0.26%	1.43%	1.43%
Total Long-Term Liabilities	$325.8M	$326.8M	$326.8M
YoY Change	0.26%	1.43%	1.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.30M	$37.44M	$37.44M
Total Long-Term Liabilities	$325.8M	$326.8M	$326.8M
Total Liabilities	$358.1M	$364.3M	$364.3M
YoY Change	-0.73%	4.6%	4.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$658.0M	-$614.1M
YoY Change	33.01%	36.32%
Common Stock	$27.00K	$27.00K
YoY Change	0.0%	-6.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$47.78M	$88.10M	$88.10M
YoY Change
Total Liabilities & Shareholders Equity	$405.8M	$452.4M	$452.4M
YoY Change	-26.45%	-25.88%	-25.88%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$43.94M	-$42.21M	-$163.6M
YoY Change	-0.72%	59.81%	27.11%
Depreciation, Depletion And Amortization	$163.0K	$165.0K	$652.0K
YoY Change	-1.81%	-10.33%	-3.41%
Cash From Operating Activities	-$37.25M	-$34.35M	-$120.8M
YoY Change	51.63%	221.47%	64.15%
INVESTING ACTIVITIES
Capital Expenditures	$27.00K	$280.0K	$807.0K
YoY Change	-84.57%	60.0%	125.42%
Acquisitions
YoY Change
Other Investing Activities	$68.64M	$49.46M	$145.6M
YoY Change	-19.78%	128.21%	-136.9%
Cash From Investing Activities	$68.62M	$49.18M	$144.8M
YoY Change	-19.65%	128.77%	-136.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$47.53M
YoY Change			301.86%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$13.63M	-5.159M	-$59.30M
YoY Change	-63.72%	-364.7%	-234.71%
NET CHANGE
Cash From Operating Activities	-$37.25M	-34.35M	-$120.8M
Cash From Investing Activities	$68.62M	49.18M	$144.8M
Cash From Financing Activities	-$13.63M	-5.159M	-$59.30M
Net Change In Cash	$17.73M	9.670M	-$35.34M
YoY Change	-23.76%	-24.22%	-91.67%
FREE CASH FLOW
Cash From Operating Activities	-$37.25M	-$34.35M	-$120.8M
Capital Expenditures	$27.00K	$280.0K	$807.0K
Free Cash Flow	-$37.28M	-$34.63M	-$121.6M
YoY Change	50.67%	218.87%	64.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28165000	shares
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-394845000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2472000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.08
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.08
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.57
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.57
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26924000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26924000	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	396731000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4800000	shares
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	800000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001370053
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.anaptysbio.com/20231231#CollaborationRevenueMember
CY2022	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.anaptysbio.com/20231231#CollaborationRevenueMember
CY2021	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.anaptysbio.com/20231231#CollaborationRevenueMember
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37985
CY2023	dei	Entity Registrant Name EntityRegistrantName	ANAPTYSBIO, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-3828755
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	10770 Wateridge Circle
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2023	dei	City Area Code CityAreaCode	858
CY2023	dei	Local Phone Number LocalPhoneNumber	362-6295
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2023	dei	Trading Symbol TradingSymbol	ANAB
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	366560992	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26763081	shares
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35965000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71308000	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	6851000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1419000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	354939000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	369933000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9080000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4545000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	406835000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	447205000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2098000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2089000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16174000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17898000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	27026000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	142935000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	256000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	256000	usd
CY2023Q4	us-gaap	Assets Assets	452389000	usd
CY2022Q4	us-gaap	Assets Assets	610383000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4698000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2784000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30967000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21633000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1777000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1637000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	37442000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26054000	usd
CY2023Q4	anab	Advance Future Royalties Liability Noncurrent AdvanceFutureRoyaltiesLiabilityNoncurrent	310807000	usd
CY2022Q4	anab	Advance Future Royalties Liability Noncurrent AdvanceFutureRoyaltiesLiabilityNoncurrent	304413000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16037000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17813000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26597000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26597000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28513000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28513000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	27000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	29000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	702969000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	717797000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-797000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5246000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-614096000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-450477000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	88103000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	262103000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	452389000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	610383000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17157000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10287000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	63175000	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	132283000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	88798000	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	98496000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41946000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	36643000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21493000	usd
CY2023	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	7339000	usd
CY2022	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	usd
CY2021	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	181568000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	125441000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	119989000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-164411000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-115154000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-56814000	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	18873000	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	7550000	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	431000	usd
CY2023	anab	Noncash Advance Future Royalties And Amortization Of Advance Future Royalties Interest Expense NoncashAdvanceFutureRoyaltiesAndAmortizationOfAdvanceFutureRoyaltiesInterestExpense	18083000	usd
CY2022	anab	Noncash Advance Future Royalties And Amortization Of Advance Future Royalties Interest Expense NoncashAdvanceFutureRoyaltiesAndAmortizationOfAdvanceFutureRoyaltiesInterestExpense	21108000	usd
CY2021	anab	Noncash Advance Future Royalties And Amortization Of Advance Future Royalties Interest Expense NoncashAdvanceFutureRoyaltiesAndAmortizationOfAdvanceFutureRoyaltiesInterestExpense	1450000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	37000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-982000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-163619000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	4449000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-4824000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-418000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-159170000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-133548000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58214000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28165000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27431000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27431000	shares
CY2021	anab	Stock Issued During Period Value Options And Employee Stock Purchase Plan StockIssuedDuringPeriodValueOptionsAndEmployeeStockPurchasePlan	2564000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	15347000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-418000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-57796000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	356428000	usd
CY2022	anab	Stock Issued During Period Value Options And Employee Stock Purchase Plan StockIssuedDuringPeriodValueOptionsAndEmployeeStockPurchasePlan	11867000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	27356000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4824000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-128724000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	262103000	usd
CY2023	anab	Stock Issued During Period Value Options And Employee Stock Purchase Plan StockIssuedDuringPeriodValueOptionsAndEmployeeStockPurchasePlan	2421000	usd
CY2023	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	50456000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	33205000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	4449000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-163619000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	88103000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-163619000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-128724000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-57796000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	652000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	675000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	619000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	33205000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	27356000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	15347000	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	10521000	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	2507000	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-493000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1724000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1660000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1471000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-18083000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-21108000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1450000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	15000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	5432000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	543000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	876000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4194000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	813000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1801000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	10938000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9700000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4740000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1636000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1505000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-72000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-120800000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73593000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45920000	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	303919000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	802503000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	118662000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	449480000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	408016000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	158848000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	15000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	807000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	358000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1366000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	144754000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	38835000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11827000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2553000	usd
CY2023	anab	Proceeds From Sale Of Advance Future Royalties ProceedsFromSaleOfAdvanceFutureRoyalties	0	usd
CY2022	anab	Proceeds From Sale Of Advance Future Royalties ProceedsFromSaleOfAdvanceFutureRoyalties	35000000	usd
CY2021	anab	Proceeds From Sale Of Advance Future Royalties ProceedsFromSaleOfAdvanceFutureRoyalties	250000000	usd
CY2023	anab	Repayment Of Advance Future Royalty And Milestones RepaymentOfAdvanceFutureRoyaltyAndMilestones	11726000	usd
CY2022	anab	Repayment Of Advance Future Royalty And Milestones RepaymentOfAdvanceFutureRoyaltyAndMilestones	2474000	usd
CY2021	anab	Repayment Of Advance Future Royalty And Milestones RepaymentOfAdvanceFutureRoyaltyAndMilestones	0	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	50000000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023	anab	Payments Of Advance Future Royalties Issuance Costs PaymentsOfAdvanceFutureRoyaltiesIssuanceCosts	43000	usd
CY2022	anab	Payments Of Advance Future Royalties Issuance Costs PaymentsOfAdvanceFutureRoyaltiesIssuanceCosts	336000	usd
CY2021	anab	Payments Of Advance Future Royalties Issuance Costs PaymentsOfAdvanceFutureRoyaltiesIssuanceCosts	255000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-59297000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	44017000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	252298000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-35343000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-424421000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	245213000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71308000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	495729000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	250516000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35965000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71308000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	495729000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	20685000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	154000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	31000	usd
CY2023	anab	Noncash Advance Future Royalties Issuance Costs Incurred But Not Yet Paid NoncashAdvanceFutureRoyaltiesIssuanceCostsIncurredButNotYetPaid	0	usd
CY2022	anab	Noncash Advance Future Royalties Issuance Costs Incurred But Not Yet Paid NoncashAdvanceFutureRoyaltiesIssuanceCostsIncurredButNotYetPaid	80000	usd
CY2021	anab	Noncash Advance Future Royalties Issuance Costs Incurred But Not Yet Paid NoncashAdvanceFutureRoyaltiesIssuanceCostsIncurredButNotYetPaid	102000	usd
CY2023	anab	Repurchase Of Common Stock Incurred But Not Yet Paid RepurchaseOfCommonStockIncurredButNotYetPaid	456000	usd
CY2022	anab	Repurchase Of Common Stock Incurred But Not Yet Paid RepurchaseOfCommonStockIncurredButNotYetPaid	0	usd
CY2023	anab	Receivable Issuance Of Common Stock Stock Options Exercised ReceivableIssuanceOfCommonStockStockOptionsExercised	-51000	usd
CY2022	anab	Receivable Issuance Of Common Stock Stock Options Exercised ReceivableIssuanceOfCommonStockStockOptionsExercised	40000	usd
CY2021	anab	Receivable Issuance Of Common Stock Stock Options Exercised ReceivableIssuanceOfCommonStockStockOptionsExercised	11000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents and certain investments in money market funds, certificates of deposit, agency securities, commercial obligations and U.S. Treasury securities. Bank deposits are diversified between three financial institutions and these deposits may exceed insured limits. We are exposed to credit risk in the event of default by the financial institutions holding our cash and cash equivalents and issuers of investments that are recorded on our consolidated balance sheets. We mitigate our risk by investing in high-grade instruments and limiting the concentration in any one issuer, which limits our exposure.</span></div>
CY2023	anab	Number Of Financial Institutions Utilized For Diversification Of Funds NumberOfFinancialInstitutionsUtilizedForDiversificationOfFunds	3	bank
CY2023	us-gaap	Property Plant And Equipment Impairment PropertyPlantAndEquipmentImpairment	<div style="margin-top:12pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long Lived Assets </span></div>Long-lived assets, consisting of property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable based on undiscounted cash flows. If long-lived assets are impaired, an impairment loss is recognized and is measured as the amount by which the carrying value exceeds the estimated fair value of the assets.
CY2023	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2021	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3977000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3631000	shares
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8316000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7665000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6218000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5576000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2098000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2089000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7201000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5379000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1168000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	607000	usd
CY2023Q4	anab	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	21898000	usd
CY2022Q4	anab	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	15351000	usd
CY2023Q4	anab	Accrued Common Stock Repurchased AccruedCommonStockRepurchased	456000	usd
CY2022Q4	anab	Accrued Common Stock Repurchased AccruedCommonStockRepurchased	0	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	244000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	296000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30967000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21633000	usd
CY2023	us-gaap	Contract With Customer Timing Of Satisfaction Of Performance Obligation And Payment ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment	Cash is generally received within 30 days of milestone achievement.
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	382555000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	199000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	789000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	381965000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	517907000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	38000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5077000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	512868000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	106530000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	120000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	132167000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	669000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	238697000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	789000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	404386000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	4144000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	62527000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	933000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	466914000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	5077000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	5100000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	700000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26596765	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26596765	shares
CY2023Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	50000000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1589424	shares
CY2023Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	24.19
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	38456000	usd
CY2023Q2	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	534790	shares
CY2023Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	21.59
CY2023Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	11544000	usd
CY2023	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	2124214	shares
CY2023	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	50000000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3673208	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.04
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M10D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	18686000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1579331	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	22.02
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	90883	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	18.95
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	936041	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	37.52
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4225615	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.36
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M1D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5827000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2154408	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	30.60
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4741000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1800000	usd
CY2023	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	33205000	usd
CY2022	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	27356000	usd
CY2021	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	15347000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.10
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	22500	usd
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2022	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	11000	usd
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	8000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1600000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1000000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	600000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.040
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M12D
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2478000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2478000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2213000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	2386000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2316000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	705000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2457000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2531000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2607000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2685000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2766000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	7788000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	20834000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3020000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	17814000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-163580000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-128650000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-57741000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-43000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-50000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-55000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-163623000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-128700000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-57796000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	72777000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	66160000	usd
CY2023Q4	anab	Deferred Tax Assets Research And Development DeferredTaxAssetsResearchAndDevelopment	37240000	usd
CY2022Q4	anab	Deferred Tax Assets Research And Development DeferredTaxAssetsResearchAndDevelopment	16570000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	19058000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	12844000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10533000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10021000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	6978000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	7371000	usd
CY2023Q4	anab	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	3912000	usd
CY2022Q4	anab	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	4194000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	7201000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3458000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	157699000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	120618000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	3552000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	3859000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2658000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	122000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	189000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6332000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4048000	usd
CY2023Q4	anab	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	151367000	usd
CY2022Q4	anab	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	116570000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	151367000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	116570000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	200000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-34361000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-27026000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-12138000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1912000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-800000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-142000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-56000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-27000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-17000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2840000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-297000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-708000	usd
CY2023	anab	Effective Income Tax Rate Reconciliation Nondeductable Compensation Amount EffectiveIncomeTaxRateReconciliationNondeductableCompensationAmount	3693000	usd
CY2022	anab	Effective Income Tax Rate Reconciliation Nondeductable Compensation Amount EffectiveIncomeTaxRateReconciliationNondeductableCompensationAmount	2060000	usd
CY2021	anab	Effective Income Tax Rate Reconciliation Nondeductable Compensation Amount EffectiveIncomeTaxRateReconciliationNondeductableCompensationAmount	0	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	6213000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3319000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-8087000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	109000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-6000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	42000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	35784000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	29385000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4842000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3369000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2473000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	153000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1494000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	896000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5016000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3369000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
0001370053-24-000011-index-headers.html	Edgar Link	pending
0001370053-24-000011-index.html	Edgar Link	pending
0001370053-24-000011.txt	Edgar Link	pending
0001370053-24-000011-xbrl.zip	Edgar Link	pending
anab-12312023x10kxexx311.htm	Edgar Link	pending
anab-12312023x10kxexx312.htm	Edgar Link	pending
anab-12312023x10kxexx321.htm	Edgar Link	pending
anab-12312023x10kxexx322.htm	Edgar Link	pending
anab-12312023xexx211.htm	Edgar Link	pending
anab-12312023xexx231.htm	Edgar Link	pending
anab-20231231.htm	Edgar Link	pending
anab-20231231.xsd	Edgar Link	pending
anab-20231231_g1.jpg	Edgar Link	pending
centessalicenseagreement.htm	Edgar Link	pending
centessalicenseagreement001.jpg	Edgar Link	pending
centessalicenseagreement002.jpg	Edgar Link	pending
centessalicenseagreement003.jpg	Edgar Link	pending
centessalicenseagreement004.jpg	Edgar Link	pending
centessalicenseagreement005.jpg	Edgar Link	pending
centessalicenseagreement006.jpg	Edgar Link	pending
centessalicenseagreement007.jpg	Edgar Link	pending
centessalicenseagreement008.jpg	Edgar Link	pending
centessalicenseagreement009.jpg	Edgar Link	pending
centessalicenseagreement010.jpg	Edgar Link	pending
centessalicenseagreement011.jpg	Edgar Link	pending
centessalicenseagreement012.jpg	Edgar Link	pending
centessalicenseagreement013.jpg	Edgar Link	pending
centessalicenseagreement014.jpg	Edgar Link	pending
centessalicenseagreement015.jpg	Edgar Link	pending
centessalicenseagreement016.jpg	Edgar Link	pending
centessalicenseagreement017.jpg	Edgar Link	pending
centessalicenseagreement018.jpg	Edgar Link	pending
centessalicenseagreement019.jpg	Edgar Link	pending
centessalicenseagreement020.jpg	Edgar Link	pending
centessalicenseagreement021.jpg	Edgar Link	pending
centessalicenseagreement022.jpg	Edgar Link	pending
centessalicenseagreement023.jpg	Edgar Link	pending
centessalicenseagreement024.jpg	Edgar Link	pending
centessalicenseagreement025.jpg	Edgar Link	pending
centessalicenseagreement026.jpg	Edgar Link	pending
centessalicenseagreement027.jpg	Edgar Link	pending
centessalicenseagreement028.jpg	Edgar Link	pending
anab-20231231_def.xml	Edgar Link	unprocessable
anab-20231231_lab.xml	Edgar Link	unprocessable
anab-20231231_pre.xml	Edgar Link	unprocessable
anab-20231231_htm.xml	Edgar Link	completed
centessalicenseagreement029.jpg	Edgar Link	pending
centessalicenseagreement030.jpg	Edgar Link	pending
centessalicenseagreement031.jpg	Edgar Link	pending
centessalicenseagreement032.jpg	Edgar Link	pending
centessalicenseagreement033.jpg	Edgar Link	pending
centessalicenseagreement034.jpg	Edgar Link	pending
centessalicenseagreement035.jpg	Edgar Link	pending
centessalicenseagreement036.jpg	Edgar Link	pending
centessalicenseagreement037.jpg	Edgar Link	pending
centessalicenseagreement038.jpg	Edgar Link	pending
centessalicenseagreement039.jpg	Edgar Link	pending
centessalicenseagreement040.jpg	Edgar Link	pending
centessalicenseagreement041.jpg	Edgar Link	pending
centessalicenseagreement042.jpg	Edgar Link	pending
centessalicenseagreement043.jpg	Edgar Link	pending
clawbackpolicyapproved9-.htm	Edgar Link	pending
clawbackpolicyapproved9-001.jpg	Edgar Link	pending
clawbackpolicyapproved9-002.jpg	Edgar Link	pending
clawbackpolicyapproved9-003.jpg	Edgar Link	pending
clawbackpolicyapproved9-004.jpg	Edgar Link	pending
clawbackpolicyapproved9-005.jpg	Edgar Link	pending
clawbackpolicyapproved9-006.jpg	Edgar Link	pending
clawbackpolicyapproved9-007.jpg	Edgar Link	pending
clawbackpolicyapproved9-008.jpg	Edgar Link	pending
clawbackpolicyapproved9-009.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tesaroamd5tolicenseagree.htm	Edgar Link	pending
tesaroamd5tolicenseagree001.jpg	Edgar Link	pending
tesaroamd5tolicenseagree002.jpg	Edgar Link	pending
tesaroamd5tolicenseagree003.jpg	Edgar Link	pending
tesaroamd5tolicenseagree004.jpg	Edgar Link	pending
tesaroamd5tolicenseagree005.jpg	Edgar Link	pending
anab-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANAB
ANAPTYSBIO, INC Stock $anab

2024 Q1 Form 10-K Financial Statement

#000137005324000011 Filed on March 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB ANAPTYSBIO, INC Stock $anab

2024 Q1 Form 10-K Financial Statement

#000137005324000011 Filed on March 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB
ANAPTYSBIO, INC Stock $anab